Ventyx Biosciences Inc Cash Flow Conversion Efficiency
Ventyx Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.51 Million) by net assets ($191.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ventyx Biosciences Inc (2019–2024)
Cash flow conversion efficiency of Ventyx Biosciences Inc from 2019 to 2024. This chart illustrates how Ventyx Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ventyx Biosciences Inc share price for real-time trading data and today's change.
Ventyx Biosciences Inc Cash Flow Conversion Ratio Explained
Ventyx Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ventyx Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ventyx Biosciences Inc ranked by their cash flow conversion efficiency. Also see VTYX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Under Armour Inc A
NYSE:UAA
|
0.194x |
|
Auto Partner SA
WAR:APR
|
-0.001x |
|
Dynamic Holding Co. Ltd.
TW:3715
|
-0.034x |
|
Superloop Ltd
AU:SLC
|
0.123x |
|
Sano Bruno's Enterprises Ltd
TA:SANO1
|
0.033x |
|
Bio-Thera Solutions Ltd
SHG:688177
|
-0.585x |
|
RITES Limited
NSE:RITES
|
-0.030x |
|
CSSC Offshore & Marine Engineering (Group) Co Ltd
F:GSZ
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Ventyx Biosciences Inc from 2019 to 2024. Review VTYX financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $254.04 Million | $-130.87 Million | -0.515x | +24.54% |
| 2023-12-31 | $243.92 Million | $-166.52 Million | -0.683x | -144.60% |
| 2022-12-31 | $353.89 Million | $-98.77 Million | -0.279x | -101.61% |
| 2021-12-31 | $279.20 Million | $-38.65 Million | -0.138x | -168.50% |
| 2020-12-31 | $-30.65 Million | $-6.20 Million | 0.202x | -68.42% |
| 2019-12-31 | $-4.13 Million | $-2.64 Million | 0.640x | -- |
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more